In vitro Activity of Plazomicin Compared to Amikacin, Gentamicin, and Tobramycin Against Multidrug Resistant Aerobic Gram-Negative Bacilli.
The worldwide spread of multidrug resistant Enterobacterales is a serious threat to public health. Here, we compared the MICs of plazomicin, amikacin, gentamicin and tobramycin against 303 multinational multidrug resistant Gram-negative bacilli. We followed Clinical and Laboratory Standards Institute (CLSI) guidelines and applied CLSI breakpoints and as well as those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for amikacin, gentamicin, and tobramycin and of the United States Food and Drug Administration for plazomicin. Overall, plazomicin demonstrated the highest percentage of susceptible isolates (80.2%) and the lowest MIC50 (1 μg/ml) of the aminoglycosides studied. Of the 42 isolates resistant to plazomicin, 34 had MICs ≥128 μg/ml, with 33 of the 34 having MICs >128 μg/ml for amikacin, gentamicin, and tobramycin. 35.7% of the 42 bla NDM-positive isolates were plazomicin susceptible, with the percentage susceptible to amikacin being 38.1% or 35.7% applying CLSI or EUCAST breakpoints, respectively. For the 20 bla OXA-48-like-positive isolates, plazomicin had the highest percentage susceptibility, with 50.0% being susceptible. Among 35 isolates with bla CTX-M as their only characterized resistance mechanism, 68.6% were plazomicin-susceptible, while the percentage susceptible to amikacin was 74.3% or 62.9% applying CLSI or EUCAST breakpoints, respectively. 94.9% of the 117 bla KPC-positive isolates were susceptible to plazomicin, compared to 43.6%/25.6%, 56.4%/44.4%, and 5.1%/4.3% (CLSI/EUCAST breakpoints) for amikacin, gentamicin, and tobramycin, respectively.